-- Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) recorded cumulative revenue of RM482.24 million for the first half of FY2026 ended 30 June 2026, which saw the Group’s Profit Before Tax (“PBT”) growing 32.1% year-on-year to RM79.71 million, while Profit After Tax (“PAT”) rose 32.2% to RM60.59 million, compared to the corresponding period in the preceding year. The profit growth was primarily driven by a more favourable product mix, the strengthening of the Malaysian Ringgit which reduced input costs for most Active Pharmaceutical Ingredients (“APIs”), and continued operational efficiencies across the Group, which offset higher operating expenses incurred in support of business growth.
At the same time, Duopharma Biotech’s combined revenue across the first two quarters of FY2026 marginally declined 0.5% from the RM484.52 million recorded in H1 FY2025, mainly attributable to the normalisation of insulin sales to the public sector following a one-off surge last year. Excluding the impact of insulin sales, the Group saw underlying revenue growth, supported by continued expansion across the private market segments and export business, with stronger contributions from the Consumer Healthcare business. Meanwhile, Q2 FY2026 revenue of RM234.36 million, declining 5.5% from the preceding quarter, was consistent with the Group’s historical sales pattern, where public sector demand normalises in the second quarter in line with the Ministry of Health’s annual procurement cycle.
Duopharma Biotech Group Chief Executive Officer Wan Amir-Jeffery Wan Abdul Majid commented, “Duopharma Biotech’s resilient financial performance comes from a healthy order book, diversified revenue streams and strong participation in the public and private healthcare sector. To maintain this trajectory, with evolving geopolitical developments and global trade uncertainties in mind, we will continue to focus on operational excellence, prudent cost management and disciplined execution of strategic priorities, while strengthening supply chain resilience through diversified API sourcing, effective inventory management and close collaboration with key suppliers.”
The Group’s contracts to supply Ministry of Health facilities also provide continued earnings visibility. These include a two-year contract to supply Insulin Injection until 5 February 2028, valued at RM52.5 million, as well as a three-year contract to supply Recombinant Human Insulin products until 2 June 2029, valued at approximately RM155.3 million. In addition, on 31 July 2026, the Group accepted Notices of Extension for the continued supply of 97 pharmaceutical and non-pharmaceutical products under the Approved Products Purchase List (“APPL”) from 1 January 2027 to 30 June 2027. The products are part of existing contracts to supply 100 products until 31 December 2026.
Dividend maintained
For the current financial period ended 30 June 2026, the Board of Directors announced an interim dividend of 1.5 sen per share, amounting to approximately RM14.43 million, maintaining the amount paid last year (2025: 1.5 sen per share). The entitlement date and payment date have been determined for 4 September 2026 and 21 September 2026 respectively.
An active industry stakeholder
Recently, the Group partnered with the Malaysian Pharmacists Society (“MPS”) to establish the MPS-Duopharma Biotech Student Excellence Award, a three-year initiative aimed at developing future pharmacy leaders. At the MPS-Duopharma Biotech Student Excellence Award 2026, held in conjunction with the Malaysian Pharmacists Society National Pharmacists Convention (MPS NPC) 2026, 19 outstanding students representing 19 participating universities were recognised for their exemplary academic achievements, highlighting Duopharma Biotech’s continued investment in nurturing talent and supporting the advancement of the pharmacy profession in Malaysia.
Duopharma Biotech was also recently recognised at the 11th Sustainability & CSR Malaysia Awards 2026, the fourth consecutive year of recognition at the prestigious national platform, and the second consecutive win in the Company of the Year (Pharmaceutical Manufacturing) ESG Leadership Award category. The Group’s consumer healthcare brands also celebrated a hat trick of wins at the Watsons Health, Wellness & Beauty (HWB) Awards 2026. FLAVETTES ® was recognised with the inaugural Best Brand Building Collaboration award and the Most Wanted Effervescent Vitamin C + Glutathione award, while CHAMPS ® was honoured with the Most Wanted Kids Chewable Vitamin C award, reflecting the continued trust and confidence consumers place in Duopharma Biotech’s brands.
Meanwhile, to celebrate the upcoming Merdeka and Malaysia Day, the Company’s market leading Vitamin C brand FLAVETTES ® launched a campaign themed ‘FLAVETTES ® Setia Menemani Setiap Generasi’, in collaboration with Tourism Malaysia, Watsons Malaysia and Kapten Batik, celebrating more than 30 years of providing immunity support across generations as well as Malaysian cultural heritage.
Release ID: 89201009
Google
RSS